Bristol-Myers Squibb Co.

NYSE:BMY   3:59:57 PM EDT
+0.65 (+1.13%)
4:00:02 PM EDT: $58.36 +0.01 (+0.02%)

Bristol-Myers Says On April 29, Will Meet With An FDA Committee To Discuss Opdivo Hepatocellular Carcinoma U.S. Indication

Published: 03/11/2021 23:41 GMT
Bristol-Myers Squibb Co. (BMY) - Bristol-myers Squibb Co - Statement on Opdivo (nivolumab) Hepatocellular Carcinoma U.S. Indication.
Bristol-myers Squibb Co - on April 29, Will Meet With an FDA Committee to Discuss Hepatocellular Carcinoma Indication for Opdivo Monotherapy.